Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Internal Medicine Journal 2026

View at publisher
Authors: Shirlene Sim, Georgia J. B. McCaughan, Andrew C.W. Zannettino, P. Joy Ho, Douglas Joshua, Dipti Talaulikar, Peter N. Mollee, Henry Miles Prince, Andrew G Spencer, Simon James Harrison, Cindy Hsin-Yu Lee, Bradley M. Augustson
+5 more Anna Kalff, Silvia Ling, Nicholas K. Weber, Angelina Yong, Hang Quach
DOI: 10.1111/imj.70329
Cited by: 0
References: 26

Abstract

Patients with newly diagnosed multiple myeloma and considered transplant ineligible (TIE) because of age, frailty and/or comorbidities now have access to highly effective therapies that can achieve deep and/or durable remission. TIE patients are a highly heterogeneous population whose biological and chronological age can vary substantially. The treatment of these patients can be challenging in clinical practice and requires a frailty-adapted, individualised approach with an emphasis on treatment deliverability and tolerability to optimise patient outcomes. Here, we summarise recommendations for TIE patients, including pre-treatment considerations, induction and maintenance therapies, and supportive care management.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Internal Medicine Journal
Volume
56
Issue
3
Pages
457–464
Publication date
8 January 2026
Language
EN